Board of Directors
Yuling Luo, Ph.D.- (See Management)
Steve Chen, Ph.D. - (See Management)
Gerald Chan, Ph.D., Co-Founder and Chairman of Morningside
Dr. Gerald Chan holds a Master of Science degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. As a scholar, he was a Research Fellow in Pathology at Harvard Medical School, and pursued cancer research at the Dana-Farber Cancer Institute. In 1986, Dr. Chan co-founded Morningside and began his career in investments.
Since 1986, Dr. Chan has been a director of publicly listed Hang Lung Group Limited. He is also a board member of several private innovative biotech companies, notably Serica Technologies Inc., a Boston based company developing soft tissue replacement solutions; MetaCure Inc., an Israeli company with an implantable device for treating obesity and diabetes; Vaccine Technology Inc., a Boston and Haikou based company developing vaccines based on a novel method of antigen presentation; Stealth Peptide Inc., a Shanghai and Maryland based company developing a series of small peptides as novel therapeutics for cardiovascular and neurodegenerative diseases; Critical Biologics Corp, a Boston based company developing novel treatment for critical care patients; and Inimex Inc., a Vancouver based company focusing on the development of next generation anti-infective small peptide drugs.
Dr. Chan serves on the advisory board of a number of universities, including the Johns Hopkins University – Nanjing University Center for Chinese and American Studies, the Environmental Health Council of the Harvard School of Public Health, the Science Advisory Council of UCLA, and the International Society of Stem Cell Research. He is a trustee of Fudan University in Shanghai, and a board member nominee for the New York Academy of Sciences.
Amy Tang
Ms. Tang joined Morningside in 2003 to focus on healthcare investment. She is a board member of several Morningside portfolio companies. Ms. Tang has first hand experience and broad relationship working with the State Food and Drug Administration (SFDA) in China. She was previously a Registration Manager at GlaxoSmithKline (China) for five years. Ms. Tang received her M.Sc. degree in Biochemistry & Molecular Biology from the Graduate School of Chinese Academy of Sciences in Beijing, her MBA from Cheung Kong Graduate School of Business, and her B.S. in English Pharmacy from Shenyang Pharmaceutical University.